Elite Sport and Development of Asthma

Condition(s) targeted: Asthma

Intervention: Seretide (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Bispebjerg Hospital

Official(s) and/or principal investigator(s):
Thomas Lund, MD, Principal Investigator, Affiliation: Respiratory and Allergy Research Unit, Department of Respiratory Medicine

Overall contact:
Thomas Lund, MD, Phone: (+45) 35316820, Email: tclund21@hotmail.com

International studies have shown that elite athletes have a high prevalence of respiratory symptoms and asthma as compared to normal subjects. It is unclear whether the increased prevalence of asthma in elite athletes reflects "traditional asthma" or whether it is a special form of "sports asthma". The treatment of elite athletes with asthma seems to vary widely, and only a few studies have focused on the treatment of elite athletes with asthma. Further knowledge of the pathogenesis of sports asthma would lead to a greater understanding and better treatment of the condition. This study will investigate the type of airway inflammation in elite athletes and examine the effect of treatment with inhaled steroids in combination with long-acting beta-agonists versus placebo in the same group.

Official title: Elite Sport and Development of Asthma

Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment

Primary outcome:

Eucapnic voluntary hyperventilation (EVH)

Exhaled Nitric Oxide

Secondary outcome:

Respiratory symptoms

Lung function

Minimum age: 18 Years. Maximum age: 35 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Elite athletes

- Informed consent

- Doctor diagnosed asthma

Exclusion Criteria:

- Current smoker or more than 10 pack-years

- Pregnancy, breast feeding or planning pregnancy during the study.

- ICS within the last 4 weeks prior to visit 1.

Thomas Lund, MD, Phone: (+45) 35316820, Email: tclund21@hotmail.com

Respiratory and Allergy Research Unit, Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen DK-2400 NV, Denmark; Recruiting
Thomas Lund, MD, Phone: (+45) 35316820, Email: tclund21@hotmail.com
Thomas Lund, MD, Principal Investigator

Starting date: September 2005
Ending date: December 2008
Last updated: November 2, 2007